SS-31 (Elamipretide)
Elamipretide, MTP-131, Bendavia, FORZINITY (brand name for Barth syndrome)
The Ground Truth Score
four plain questions, never one numberFDA-approved for one ultra-rare disease, but its big Phase 3 trial for the broader indication it was built for missed both endpoints.
Bottom line
SS-31 is a synthetic mitochondria-targeting tetrapeptide developed at Cornell in the early 2000s; it earned FDA accelerated approval in September 2025 for Barth syndrome (a rare cardiolipin disorder), but its Phase 3 MMPOWER-3 trial in 218 patients with primary mitochondrial myopathy failed to hit either primary endpoint, and wellness-community use for longevity and energy is built entirely on mechanistic reasoning plus small disease-population data, not healthy-human evidence.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓No established human protocol for healthy adults. Clinical trials used 40 mg SubQ once daily. Community reports 1 to 5 mg SubQ daily, 5 days on / 2 days off.
Reported, not prescribed. Verify your vial and your math.
The gist
- FDA approved for one ultra-rare cardiolipin disorder (Barth syndrome, Sept 2025), but the 218-person Phase 3 trial for the broader mitochondrial myopathy population missed both primary endpoints at 24 weeks.
- The mechanism is the most solid part of the story: it really does bind cardiolipin in the inner mitochondrial membrane in biochemical studies, and cardiolipin really does matter for electron transport chain efficiency.
- Community doses (1 to 5 mg/day) are an order of magnitude below the 40 mg/day used in every clinical trial, which itself failed to beat placebo. Nobody can tell you what that gap means for healthy users.
First documented human use
Circa 2013-2015, Phase I/II dose-escalation safety study in adults with primary mitochondrial myopathy, sponsored by Stealth BioTherapeutics. The trial number NCT01786941 and the 2010 start date cited in some sources could not be independently confirmed against the ClinicalTrials.gov registry and should be treated as unverified; the SPIMM-201 Phase 1/2 IV-dose study is the earliest published human dataset.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- Claimed to recharge mitochondria by stabilizing cardiolipin in the inner mitochondrial membrane
- Marketed as a cellular energy amplifier that increases ATP output and reduces reactive oxygen species
- Promoted for age-related decline, muscle fatigue, and exercise performance in wellness contexts
- Positioned as a heart and kidney protector via mitochondrial preservation
- Sold to longevity biohackers as the first mitochondria-targeted peptide with FDA validation
The data behind each bullet
What actually backs it
Improves muscle strength and function in mitochondrial disease
FDA accelerated approval for Barth syndrome rests on open-label extension data (n=8 through week 168) showing improved 6-minute walk test and symptom scores; the randomized TAZPOWER phase did not show significant change in knee extensor strength. MMPOWER-3 (n=218, PMM patients) failed both primary endpoints at 24 weeks.
Efficacy and Safety of Elamipretide in PMM: MMPOWER-3 RCT (Neurology, 2023) ↗Stabilizes mitochondrial cristae structure by binding cardiolipin
Mechanism is well-characterized in biochemical and cell studies; cardiolipin binding and cristae stabilization confirmed across multiple independent laboratories. This is the strongest part of the evidence base, though functional consequences in humans remain uncertain beyond rare disease populations.
Elamipretide: Structure, Mechanism of Action, and Therapeutic Potential (IJMS, 2025, PMC11816484) ↗Slows progression of geographic atrophy in dry age-related macular degeneration
ReCLAIM-2, a Phase II placebo-controlled trial (n=~100), showed slowed ellipsoid zone loss (a surrogate endpoint) but did not demonstrate functional vision improvement. Phase III is planned using EZ preservation as the primary endpoint per FDA agreement.
ReCLAIM-2 Phase II AMD Trial (Ophthalmology Science, 2024, PMC11599447) ↗Improves cardiac function and mitochondrial output in heart failure
Human cardiac trials exist and both failed their primary endpoints. PROGRESS-HF (n=71, HFrEF, 28 days) found no significant reduction in left ventricular end-systolic volume at 4 weeks for either 4 mg or 40 mg vs placebo. EMBRACE-STEMI (Phase 2a, first-time anterior STEMI, primary PCI) found no decrease in myocardial infarct size vs placebo. A January 2026 rodent HFpEF study (PMC12841679) found elamipretide modestly improved complex I and II respiration but produced no functional or structural cardiac benefit once HFpEF was established, reinforcing the pattern of mechanistic signal without functional translation. Strong preclinical data in dog models of heart failure exist (PMC4743543) but cannot substitute for the failed human trial evidence. Grade is C (human trials conducted, none showed benefit on primary endpoint) rather than D (animal-only).
PROGRESS-HF Phase 2 Trial: no significant LVESV reduction (Journal of Cardiac Failure, 2020, PMID 32068002) ↗Boosts energy and reduces fatigue in healthy users or longevity-seeking adults
No controlled trial exists in healthy adults. Community reports exist but no objective data. The MMPOWER-3 fatigue scale failed to separate from placebo even in patients with diagnosed mitochondrial disease.
MMPOWER-3 Phase 3 RCT: failed fatigue primary endpoint (NCT03323749, ClinicalTrials.gov) ↗Mechanism
How it's assumed to work
Assumed · theoretical pathway
ASSUMED based on in vitro and animal data, partially supported in human disease populations. SS-31 is a cell-penetrating tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that concentrates ~1000-fold in the inner mitochondrial membrane via electrostatic and hydrophobic interactions. Once localized, it binds cardiolipin, a phospholipid critical for cristae architecture and electron transport chain supercomplex assembly. By stabilizing cardiolipin, SS-31 is theorized to preserve mitochondrial membrane potential, improve electron transfer efficiency, reduce reactive oxygen species production at complexes I and III, and support ATP synthesis. Whether this translates to meaningful functional improvement in humans without mitochondrial pathology is not established.
Dosing & handling
What users and clinicians report
Community protocols typically report 3 to 5 mg subcutaneous injection daily or 5 days on / 2 days off. Some sources cite 40 mg/day matching clinical trial doses, but this is the dose used in disease populations under medical supervision. Most biohacker sources suggest 1 to 5 mg/day as a starting range. No oral formulation is bioavailable.
Reported doses only, never prescribed. The biggest dosing risk is sourcing: compounded or research-chemical SS-31 has no sterility or purity guarantees matching pharmaceutical FORZINITY. The clinical 40 mg/day dose failed to beat placebo in the largest trial; lower community doses have even less basis. Peptide degradation from improper reconstitution or storage can render the compound inactive.
Timing & food
Clinical trials used once-daily subcutaneous injection with no established time-of-day requirement. Community protocols frequently use morning dosing on the premise that mitochondrial function peaks during daytime metabolic activity, but there is no trial data supporting timing optimization in humans.
Half-life
Approximately 2 hours plasma half-life after subcutaneous injection, based on pharmacokinetic data from Phase 1 dose-escalation study. Mitochondrial dwell time may exceed plasma half-life due to preferential accumulation in mitochondrial membrane.
Reconstitution sensitivity
Lyophilized SS-31 is relatively stable if stored frozen and protected from light. Reconstituted solution should be used within 24 hours if refrigerated; not validated for extended storage after reconstitution. The dipeptide tyrosine analog (2-prime-6-prime-dimethyltyrosine) is susceptible to oxidation; antioxidant-free reconstitution with bacteriostatic water is the standard practice in compounded formulations.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Moderate community discussion in longevity and biohacker forums (Reddit r/Peptides, Longecity, various wellness blogs). Volume has grown significantly since FDA approval in 2025 gave it mainstream legitimacy.
Consistency
Inconsistent. Reports of improved energy and recovery are common but highly variable. A subset of users report nothing. The pattern mirrors what you would expect from a peptide with a real mechanism but uncertain human efficacy outside specific disease states.
Source credibility
Low to moderate. Most community reports come from people also on TRT or other compounds. No n-of-1 well-controlled biohacker reports exist. The clinical trial failure in PMM patients (a population with actual mitochondrial dysfunction) suggests healthy-user effects are likely smaller or absent.
- Anecdote: users commonly report a subtle but noticeable increase in stamina and reduced workout recovery time within 2 to 4 weeks, though this is nearly impossible to separate from concurrent TRT or BPC-157 use.
- Anecdote: a subset of biohacker forum users report no perceptible effect at doses of 1 to 5 mg/day, consistent with the clinical trial fatigue data showing no separation from placebo even at 40 mg/day in disease populations.
- Anecdote: several long-term users (6+ months) describe subjective cognitive clarity improvements, which is not a studied endpoint in any trial and is highly susceptible to expectation effect.
- Anecdote: injection site itching and mild redness lasting 30 to 60 minutes is reported by a majority of community users who inject subcutaneously, matching the clinical trial adverse event profile closely.
Placebo risk, High
Primary marketed benefits (more energy, faster recovery, better mental clarity) are highly subjective. MMPOWER-3 failed its fatigue endpoint in patients with diagnosed mitochondrial disease, meaning even objective fatigue measurement in disease could not distinguish drug from placebo over 24 weeks. In healthy adults reporting subjective energy improvements, placebo contribution is essentially unquantifiable.
Risk panel
What could go wrong
Adverse events
Injection site reactions are the dominant adverse event across all clinical trials, reported in up to 86% of elamipretide-treated participants vs 71% placebo in ReCLAIM-2. Reactions include pruritus, pain, bruising, and erythema at the injection site. Mild headache and nausea reported in a minority. No serious systemic adverse events attributed to elamipretide in published Phase 1/2 data across MMPOWER-3 (n=218), TAZPOWER (n=12, OLE to 168 weeks), PROGRESS-HF, EMBRACE-STEMI, and ReCLAIM-2. No fatal AEs reported. ECG, vital signs, and serum chemistry showed no clinically significant changes attributable to elamipretide across trials. 168-week TAZPOWER OLE added no new safety signals.
Theoretical concerns
Cardiolipin modulation affects multiple mitochondrial processes including apoptosis signaling; theoretical concern that systemic cardiolipin stabilization could interfere with normal programmed cell death in rapidly dividing cells (immune cells, gut epithelium). Not observed in trials to date but long-term data beyond 4 years is limited even in disease populations.
Contraindications
No established contraindications published for the Barth syndrome indication. Use in pregnancy, lactation, pediatrics under 30 kg, or severe hepatic/renal failure is not characterized. Compounded peptide sources carry additional sterility and purity risks not present in the pharmaceutical formulation.
Honest unknowns
Long-term effects (beyond 3-4 years) in humans are unknown. Effects in healthy adults with normal mitochondrial function are not studied. Optimal dosing, cycling, and duration for any off-label purpose are entirely undefined by controlled data. A 2026 rodent HFpEF study found mechanistic improvement in mitochondrial respiration that did not translate into functional cardiac benefit, raising the question of whether the mechanism alone is sufficient to produce clinical endpoints in established disease states.
Confound watch
Wellness users who report energy and recovery improvements are almost always also on TRT, GLP-1 agonists, or peptide stacks (BPC-157, CJC-1295, TB-500). TRT alone substantially improves mitochondrial density and energy. GLP-1 agonists reduce inflammatory fat mass which improves baseline energy. Stacking SS-31 on top of these makes attribution essentially impossible. Community reports should be read with this baseline-effect lens.
History
Discovery → first use → status
- Early 2000sDrs. Hazel Szeto and Peter Schiller at Cornell University develop the SS peptide series (Szeto-Schiller), identifying SS-31 as a cell-penetrating tetrapeptide that selectively accumulates in mitochondria via cardiolipin binding.
- 2006Hazel Szeto founds Stealth BioTherapeutics to advance SS-31 (initially called Bendavia, later MTP-131) toward clinical development.
- 2016EMBRACE-STEMI Phase 2a trial (PMID 26586786) published in European Heart Journal: IV elamipretide in first-time anterior STEMI patients undergoing PCI found no decrease in myocardial infarct size vs placebo.
- 2018-2023Phase 1/2 MMPOWER study shows early promise in mitochondrial myopathy. Phase 3 MMPOWER-3 enrolls 218 patients; results released 2023 show failure on both primary endpoints (6-minute walk test and fatigue scale).
- 2020PROGRESS-HF Phase 2 trial (PMID 32068002) published in Journal of Cardiac Failure: 71 HFrEF patients randomized to placebo, 4 mg, or 40 mg elamipretide for 28 days; no significant improvement in left ventricular end-systolic volume at 4 weeks.
- September 2025FDA grants accelerated approval to FORZINITY (elamipretide HCl) for Barth syndrome, the first FDA-approved mitochondria-targeted therapeutic. Approval based largely on open-label extension data; continued approval contingent on confirmatory trial results.
Verification
The COA standard, applied
Compiled from the cited sources below. Where no completed human trial exists, the grade says so.
The full verification standard →Sources
Where this comes from
- FDA press announcement: Accelerated Approval for Barth Syndrome (September 2025) ↗· Official FDA announcement confirming September 2025 accelerated approval of FORZINITY for Barth syndrome; notes approval contingent on confirmatory trial.
- MMPOWER-3 Phase 3 RCT full paper (PMC10382259, Neurology 2023) ↗· 218-patient placebo-controlled trial; both primary endpoints (6MWT and PMMSA fatigue) failed to reach statistical significance. Key paper for calibrating efficacy expectations.
- Elamipretide structure, mechanism, and therapeutic potential review (PMC11816484, IJMS 2025) ↗· Peer-reviewed comprehensive review covering cardiolipin binding mechanism, cristae stabilization, and overview of human trial landscape through 2024.
- ReCLAIM-2 Phase II AMD trial (PMC11599447, Ophthalmology Science 2024) ↗· Phase II placebo-controlled trial in dry AMD geographic atrophy showing surrogate endpoint (ellipsoid zone preservation) improvement. No functional vision benefit demonstrated.
- PROGRESS-HF Phase 2 Trial: elamipretide in HFrEF (PMID 32068002, Journal of Cardiac Failure 2020) ↗· 71-patient double-blind RCT; neither 4 mg nor 40 mg elamipretide improved left ventricular end-systolic volume vs placebo at 4 weeks. Primary endpoint failed.
- EMBRACE-STEMI Phase 2a Trial: elamipretide in anterior STEMI (PMID 26586786, European Heart Journal 2016) ↗· Phase 2a multicenter RCT by Gibson et al.; IV elamipretide during primary PCI did not reduce myocardial infarct size vs placebo. Primary endpoint failed.
- Mitochondrial Targeting by Elamipretide Improves Myocardial Bioenergetics Without Translating into Functional Benefits in HFpEF (PMC12841679, IJMS January 2026) ↗· Rodent HFpEF model (obese ZSF1 rats, 12 weeks). Elamipretide modestly improved complex I and II respiration; mitochondrial ultrastructure, cardiolipin composition, and tafazzin expression unchanged. No functional or structural cardiac benefit observed. Reinforces the mechanistic-signal-without-functional-translation pattern seen in human trials.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.